September 3, 2008
Daiichi Sankyo Reports Positive Data for Anticoagulant Drug
Japan-based pharmaceutical company Daiichi Sankyo Company has announced positive data from the clinical study of DU-176b, an oral anticoagulant that directly inhibits Factor Xa, a clotting factor in the blood.
The data showed that DU-176b reduced the incidence of venous thromboembolism compared with dalteparin among patients undergoing elective unilateral hip replacement surgery. There was a statistically significant dose response in efficacy (P
Daiichi Sankyo is said to be developing DU-176b as a potential new treatment for the prevention of both arterial and venous thromboembolism.
John Alexander, president of pharma development at Daiichi Sankyo, said: "We expect to commence Phase III studies for DU-176b, targeting patients with atrial fibrillation, before the end of 2008."